Novo Nordisk Announce 750 Million Kroner Investment in R&D Lab
Novo Nordisk has confirmed that they are investing around 750 million kroner (roughly equivalent to $130 million) on new diabetes laboratories at the R&D campus in Måløv, Denmark.
Construction of the new laboratories has already started and the new facility, to be named the Diabetes Research House, will open in early 2016.
The Diabetes Research House will house 350 employees, proving employees with “an environment for cutting-edge diabetes research within biotechnology and protein chemistry,” according to Novo Nordisk’s chief science officer, Mads Krogsgaard.
The building will comprise of two laboratory wings, a middle building with office space, and an auditorium which will seat 450 people.
The announcement of the invest comes after Novo Nordisk posted positive third-quarter results last week, showing that net profits increased 1% to 6.50 billion kroner, while sales grew by 8% to 22.25 billion kroner.